XML 57 R32.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaborations and Other Arrangements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions | The table below summarizes significant milestones (deferred) capitalized for the compounds included in this collaboration:
Product Family |  | Milestones (Deferred) Capitalized(1)
Trajenta(2) |  | $ | 446.4 |
Jardiance(3) |  | 289.0 |
Basaglar |  | (250.0) |
(1) In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period. (2) The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto. (3) The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto. The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:
| 2020 |  | 2019 |  | 2018
Basaglar | $ | 1,124.4 |  |  | $ | 1,112.6 |  |  | $ | 801.2 |
Jardiance | 1,153.8 |  |  | 944.2 |  |  | 658.3 |
Trajenta | 358.5 |  |  | 590.6 |  |  | 574.7 |
The following table summarizes our net product revenue recognized with respect to Olumiant:
| 2020 |  | 2019 |  | 2018
Olumiant | $ | 638.9 |  |  | $ | 426.9 |  |  | $ | 202.5 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration